{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:16:38Z","timestamp":1789402598722,"version":"build-2803163510"},"reference-count":149,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1177305"],"award-info":[{"award-number":["1177305"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["RG20-07"],"award-info":[{"award-number":["RG20-07"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","award":["PW18-03"],"award-info":[{"award-number":["PW18-03"]}],"id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Li Ka Shing","award":["Cell & Gene Therapy Initiative"],"award-info":[{"award-number":["Cell & Gene Therapy Initiative"]}]},{"name":"CSR Australia","award":["Project Fund"],"award-info":[{"award-number":["Project Fund"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options and poor prognosis. MPM originates from the mesothelial lining of the pleura. Mesothelin (MSLN) is a glycoprotein expressed at low levels in normal tissues and at high levels in MPM. Many other solid cancers overexpress MSLN, and this is associated with worse survival rates. However, this association has not been found in MPM, and the exact biological role of MSLN in MPM requires further exploration. Here, we discuss the current research on the diagnostic and prognostic value of MSLN in MPM patients. Furthermore, MSLN has become an attractive immunotherapy target in MPM, where better treatment strategies are urgently needed. Several MSLN-targeted monoclonal antibodies, antibody\u2013drug conjugates, immunotoxins, cancer vaccines, and cellular therapies have been tested in the clinical setting. The biological rationale underpinning MSLN-targeted immunotherapies and their potential to improve MPM patient outcomes are reviewed.<\/jats:p>","DOI":"10.3390\/cancers13163932","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T08:47:52Z","timestamp":1628066872000},"page":"3932","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Hitting the Bull\u2019s-Eye: Mesothelin\u2019s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6546-1209","authenticated-orcid":false,"given":"Dannel","family":"Yeo","sequence":"first","affiliation":[{"name":"Li Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW 2050, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia"},{"name":"Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney Local Health District (SLHD), Camperdown, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5037-8595","authenticated-orcid":false,"given":"Laura","family":"Castelletti","sequence":"additional","affiliation":[{"name":"Li Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW 2050, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia"},{"name":"Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney Local Health District (SLHD), Camperdown, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8405-9688","authenticated-orcid":false,"given":"Nico","family":"van Zandwijk","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia"},{"name":"Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney Local Health District (SLHD), Camperdown, NSW 2050, Australia"},{"name":"Concord Repatriation General Hospital, Sydney Local Health District (SLHD), Concord, NSW 2139, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-807X","authenticated-orcid":false,"given":"John E. J.","family":"Rasko","sequence":"additional","affiliation":[{"name":"Li Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW 2050, Australia"},{"name":"Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia"},{"name":"Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney Local Health District (SLHD), Camperdown, NSW 2050, Australia"},{"name":"Gene and Stem Cell Therapy Program, Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/oemed-2017-104298","article-title":"Estimation of the global burden of mesothelioma deaths from incomplete national mortality data","volume":"74","author":"Odgerel","year":"2017","journal-title":"Occup. Environ. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1900953","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"55","author":"Scherpereel","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14737140.2020.1745067","article-title":"Asbestos-related cancers: The \u2019Hidden Killer\u2019 remains a global threat","volume":"20","author":"Reid","year":"2020","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jclinpath-2013-201609","article-title":"Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA","volume":"66","author":"Henderson","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jclinpath-2012-201303","article-title":"Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers","volume":"66","author":"Henderson","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Klebe, S., and Henderson, D.W. (2011). Early Stages of Mesothelioma, Screening and Biomarkers, Springer Science and Business Media LLC.","DOI":"10.1007\/978-3-642-10862-4_10"},{"key":"ref_7","first-page":"2493","article-title":"Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review","volume":"35","author":"Blomberg","year":"2015","journal-title":"Anticancer. Res."},{"key":"ref_8","first-page":"51","article-title":"New and emerging therapeutic options for malignant pleural mesothelioma: Review of early clinical trials","volume":"7","author":"Kotova","year":"2015","journal-title":"Cancer Manag. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Van Zandwijk, N., Reid, G., and Baas, P. (2020). Editorial: Emerging Therapies for Malignant Mesothelioma. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00939"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin Is Not Required for Normal Mouse Development or Reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The Role of Mesothelin in Tumor Progression and Targeted Therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Weidemann, S., Gagelmann, P., Gorbokon, N., Lennartz, M., Menz, A., Luebke, A., Kluth, M., Hube-Magg, C., Blessin, N., and Fraune, C. (2021). Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040397"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_18","first-page":"1741","article-title":"Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer","volume":"19","author":"Inoue","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10549-014-3077-5","article-title":"Mesothelin expression is associated with poor outcomes in breast cancer","volume":"147","author":"Li","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Winter, J.M., Tang, L.H., Klimstra, D.S., Brennan, M.F., Brody, J.R., Rocha, F.G., Jia, X., Qin, L.-X., D\u2019Angelica, M.I., and DeMatteo, R.P. (2012). A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers. PLoS ONE, 7.","DOI":"10.1371\/annotation\/2533f354-bbec-404a-9661-2c052963b918"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.21037\/tcr-19-2027","article-title":"Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma","volume":"9","author":"Feng","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100260","DOI":"10.1016\/j.ctarc.2020.100260","article-title":"Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland","volume":"25","author":"Vizcaya","year":"2020","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A Binding Domain on Mesothelin for CA125\/MUC16","volume":"284","author":"Kaneko","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of Ovarian Cancer Antigen CA125\/MUC16 to Mesothelin Mediates Cell Adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-017-0633-8","article-title":"Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells","volume":"16","author":"He","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Melaiu, O., Stebbing, J., Lombardo, Y., Bracci, E., Uehara, N., Bonotti, A., Cristaudo, A., Foddis, R., Mutti, L., and Barale, R. (2014). MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085935"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.hoc.2005.09.007","article-title":"Detection of Malignant Mesothelioma in Asbestos-Exposed Individuals: The Potential Role of Soluble Mesothelin-Related Protein","volume":"19","author":"Creaney","year":"2005","journal-title":"Hematol. Clin. N. Am."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/1055-9965.EPI-20-0083","article-title":"Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network","volume":"29","author":"Pass","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/carcin\/bgz103","article-title":"Biomarkers for malignant pleural mesothelioma: A meta-analysis","volume":"40","author":"Gillezeau","year":"2019","journal-title":"Carcinogenesis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.21037\/jtd.2017.10.132","article-title":"Serum mesothelin and other biomarkers: What have we learned in the last decade?","volume":"10","author":"Cristaudo","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ejso.2018.02.010","article-title":"Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study","volume":"44","author":"Bruno","year":"2018","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102949","DOI":"10.1016\/j.critrevonc.2020.102949","article-title":"Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review","volume":"150","author":"Ahmadzada","year":"2020","journal-title":"Crit. Rev. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3389\/fonc.2020.00445","article-title":"Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation","volume":"10","author":"Ferrari","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.molonc.2014.11.007","article-title":"MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma","volume":"9","author":"Kirschner","year":"2015","journal-title":"Mol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.21873\/cgp.20183","article-title":"Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome","volume":"17","author":"Lacerenza","year":"2020","journal-title":"Cancer Genom. Proteom."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ledda, C., Senia, P., and Rapisarda, V. (2018). Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. Cancers, 10.","DOI":"10.3390\/cancers10060203"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.21037\/tlcr.2017.05.06","article-title":"Diagnostic and prognostic biomarkers for malignant mesothelioma: An update","volume":"6","author":"Chen","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/oem.2005.023200","article-title":"The French National Mesothelioma Surveillance Program","volume":"63","author":"Goldberg","year":"2006","journal-title":"Occup. Environ. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jtho.2016.12.006","article-title":"Improving the Accuracy of Mesothelioma Diagnosis in China","volume":"12","author":"Guo","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5858\/arpa.2010-0604-RA","article-title":"Immunohistochemistry and Molecular Diagnostics of Pleural Malignant Mesothelioma","volume":"136","author":"Betta","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Porcel, J.M. (2018). Biomarkers in the diagnosis of pleural diseases: A 2018 update. Ther. Adv. Respir. Dis., 12.","DOI":"10.1177\/1753466618808660"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma","volume":"16","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1164\/rccm.200811-1729OC","article-title":"Clinical Impact and Reliability of Pleural Fluid Mesothelin in Undiagnosed Pleural Effusions","volume":"180","author":"Davies","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1183\/09031936.00226111","article-title":"Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma","volume":"41","author":"Pantazopoulos","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-020-01449-2","article-title":"Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC\/mesothelin expression","volume":"21","author":"Kojima","year":"2020","journal-title":"Respir. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/1055-9965.EPI-10-0346","article-title":"Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma","volume":"19","author":"Creaney","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00420-013-0853-1","article-title":"Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers","volume":"87","author":"Felten","year":"2013","journal-title":"Int. Arch. Occup. Environ. Health"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000355687","article-title":"Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma A Prospective Study on Italian Workers Exposed to Asbestos","volume":"86","author":"Filiberti","year":"2014","journal-title":"Oncology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00204-010-0580-2","article-title":"Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos","volume":"85","author":"Gube","year":"2010","journal-title":"Arch. Toxicol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/mco.2013.197","article-title":"Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma","volume":"2","author":"Hirohashi","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200802-258OC","article-title":"Soluble Mesothelin-related Protein in an Asbestos-exposed Population","volume":"178","author":"Park","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.lungcan.2011.01.011","article-title":"Mesothelin and kidney function\u2014Analysis of relationship and implications for mesothelioma screening","volume":"73","author":"Boudville","year":"2011","journal-title":"Lung Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3389\/fgene.2020.00975","article-title":"Variation rs2235503 C > A within the Promoter of MSLN Affects Transcriptional Rate of Mesothelin and Plasmatic Levels of the Soluble Mesothelin-Related Peptide","volume":"11","author":"Silvestri","year":"2020","journal-title":"Front. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"46425","DOI":"10.18632\/oncotarget.17436","article-title":"Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: A meta-analysis","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2478\/raon-2020-0011","article-title":"Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases","volume":"54","author":"Goricar","year":"2020","journal-title":"Radiol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1378\/chest.11-0129","article-title":"The Effect of Clinical Covariates on the Diagnostic and Prognostic Value of Soluble Mesothelin and Megakaryocyte Potentiating Factor","volume":"141","author":"Hollevoet","year":"2012","journal-title":"Chest"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.21873\/anticanres.13719","article-title":"Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma","volume":"39","author":"Fontana","year":"2019","journal-title":"Anticancer. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: Prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2021.01.011","article-title":"Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial","volume":"154","author":"Katz","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5301\/jbm.5000229","article-title":"Serum Mesothelin, Osteopontin and Vimentin: Useful Markers for Clinical Monitoring of Malignant Pleural Mesothelioma","volume":"32","author":"Bonotti","year":"2017","journal-title":"Int. J. Biol. Markers"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","article-title":"Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma during Treatment","volume":"179","author":"Grigoriu","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_71","first-page":"1","article-title":"A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma","volume":"18","author":"Arnold","year":"2018","journal-title":"BMC Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","article-title":"Soluble Mesothelin-Related Peptide and Osteopontin as Markers of Response in Malignant Mesothelioma","volume":"28","author":"Yang","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of Response and Progression to Immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/874212","article-title":"Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum","volume":"35","author":"Creaney","year":"2013","journal-title":"Dis. Markers"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2008.02.012","article-title":"Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin","volume":"62","author":"Iwahori","year":"2008","journal-title":"Lung Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00408-019-00244-1","article-title":"Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma","volume":"197","author":"Casjens","year":"2019","journal-title":"Lung"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1373\/jalm.2017.025015","article-title":"Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer","volume":"3","author":"Yu","year":"2018","journal-title":"J. Appl. Lab. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3892\/etm.2011.225","article-title":"Feasibility of large-scale screening using N-ERC\/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma","volume":"2","author":"Imashimizu","year":"2011","journal-title":"Exp. Ther. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00282","article-title":"Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma","volume":"2","author":"Cao","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: A new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00404-018-4933-z","article-title":"Mesothelin as a target for cervical cancer therapy","volume":"299","author":"Lazzerini","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1038\/srep09928","article-title":"New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes on Mesothelin For Monitoring And Treating Mesothelioma","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/ijc.25557","article-title":"A novel high-affinity human monoclonal antibody to mesothelin","volume":"128","author":"Ho","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/imt.16.4","article-title":"Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy","volume":"8","author":"Stashwick","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_92","first-page":"1","article-title":"Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","article-title":"Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development","volume":"11","author":"Kelly","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_94","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Fujii, Y., Kamachi, H., Matsuzawa, F., Mizukami, T., Kobayashi, N., Fukai, M., and Taketomi, A. (2021). Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model. Investig. New Drugs, 1\u201311.","DOI":"10.21203\/rs.3.rs-322672\/v1"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07722-3","article-title":"Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells","volume":"21","author":"Matsuzawa","year":"2021","journal-title":"BMC Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.18632\/oncotarget.2883","article-title":"Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging","volume":"6","author":"Lindenberg","year":"2015","journal-title":"Oncotarget"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00280-016-2984-z","article-title":"Population pharmacokinetics and exposure\u2013response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection","volume":"77","author":"Gupta","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","article-title":"Inhibition of mesothelin\u2013CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy","volume":"68","author":"Hassan","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1080\/15384047.2018.1449614","article-title":"CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients","volume":"19","author":"Nicolaides","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody\u2013Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/2212697X03666160218215744","article-title":"Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors","volume":"3","author":"Zhao","year":"2016","journal-title":"Clin. Cancer Drugs"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2016.34.15_suppl.2509","article-title":"Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR)","volume":"34","author":"Blumenschein","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody\u2013Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00404-020-05734-9","article-title":"Favorable therapeutic response after anti-Mesothelin antibody\u2013drug conjugate treatment requires high expression of Mesothelin in tumor cells","volume":"302","author":"Lazzerini","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.328","article-title":"OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma","volume":"12","author":"Kindler","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"A095","DOI":"10.1158\/1535-7163.TARG-17-A095","article-title":"Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer","volume":"17","author":"Hassan","year":"2018","journal-title":"Mol. Cancer. Ther."},{"key":"ref_110","first-page":"B057","article-title":"BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors","volume":"18","author":"Clarke","year":"2019","journal-title":"Immune Modul."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1158\/1078-0432.CCR-18-3476","article-title":"Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers","volume":"25","author":"Hagemann","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Macura, S.L., Steinbacher, J.L., MacPherson, M.B., Lathrop, M.J., Sayan, M., Hillegass, J.M., Beuschel, S.L., Perkins, T.N., Spiess, P.C., and Van Der Vliet, A. (2013). Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-400"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Alfaleh, M., Howard, C.B., Sedliarou, I., Jones, M.L., Gudhka, R., Vanegas, N., Weiss, J., Suurbach, J.H., de Bakker, C., and Milne, M.R. (2017). Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186137"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Pavlakis","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00002371-200007000-00011","article-title":"Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma","volume":"23","author":"Hassan","year":"2000","journal-title":"J. Immunother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1158\/1078-0432.CCR-07-1592","article-title":"Anti\u2013Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3389\/fimmu.2020.01261","article-title":"Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation","volume":"11","author":"Mazor","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/1078-0432.CCR-16-1667","article-title":"Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response","volume":"23","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1078-0432.CCR-19-2586","article-title":"Phase I\/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma","volume":"26","author":"Alewine","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Hagerty, B.L., Pegna, G.J., Xu, J., Tai, C.-H., and Alewine, C. (2020). Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. Biomolecules, 10.","DOI":"10.3390\/biom10070973"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"13832","DOI":"10.1073\/pnas.0406035101","article-title":"Listeria-based cancer vaccines that segregate immunogenicity from toxicity","volume":"101","author":"Brockstedt","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2018.03.032","article-title":"Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation","volume":"425","author":"Chen","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-7-15","article-title":"A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma","volume":"7","author":"Yuan","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00264-1","article-title":"Anti-Mesothelin CAR T cell therapy for malignant mesothelioma","volume":"9","author":"Castelletti","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: The CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Hamieh","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/2326-6066.CIR-17-0530","article-title":"AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression","volume":"6","author":"Li","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Adusumilli, P.S., Zauderer, M.G., Riviere, I., Solomon, S.B., Rusch, V.W., Cearbhaill, R.E., Zhu, A., Cheema, W., Chintala, N.K., and Halton, E. (2021). A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov.","DOI":"10.1158\/2159-8290.CD-21-0407"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"CT105","DOI":"10.1158\/1538-7445.AM2021-CT105","article-title":"Preliminary safety and efficacy of gavocabtagene autoleucel (gavo-cel, TC-210), a T cell receptor fusion construct (TRuC\u2122), in patients with treatment refractory mesothelin overexpressing solid tumors","volume":"81","author":"Hong","year":"2021","journal-title":"Cancer Res."},{"key":"ref_144","first-page":"LB-378","article-title":"Abstract LB-378: Regional delivery of clinical-grade mesothelin-targeted CAR T cells with cell-intrinsic PD-1 checkpoint blockade: Translation to a phase I trial","volume":"80","author":"Kiesgen","year":"2020","journal-title":"Bioinform. Converg. Sci. Syst. Biol."},{"key":"ref_145","first-page":"2190","article-title":"Abstract 2190: Engineering off-the-shelf T cell receptor fusion construct (TRuC) T cells","volume":"80","author":"Donaghey","year":"2020","journal-title":"Immunology"},{"key":"ref_146","first-page":"A109","article-title":"98 ATA3271: An armored, next-generation off-the-shelf, allogeneic, mesothelin-CAR T cell therapy for solid tumors","volume":"8","author":"Liu","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbrc.2020.01.053","article-title":"Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer","volume":"524","author":"Cao","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/16\/3932\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:40:18Z","timestamp":1760164818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/16\/3932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":149,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["cancers13163932"],"URL":"https:\/\/doi.org\/10.3390\/cancers13163932","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]}}}